Pasto B, Vida R, Dri A, Foffano L, Della Rossa S, Gerratana L
Breast. 2024; 79:103859.
PMID: 39708442
PMC: 11872398.
DOI: 10.1016/j.breast.2024.103859.
Sadaf , Hazazi A, Alkhalil S, Alsaiari A, Gharib A, Alhuthali H
Biomedicines. 2023; 11(8).
PMID: 37626655
PMC: 10452497.
DOI: 10.3390/biomedicines11082159.
Shamshiri A, Alidoust M, Hemmati Nokandei M, Pasdar A, Afzaljavan F
Clin Transl Oncol. 2023; 25(6):1729-1747.
PMID: 36639603
DOI: 10.1007/s12094-022-03071-8.
Li L, Wang Y, Wang Z, Xue D, Dai C, Gao X
Stem Cell Res Ther. 2022; 13(1):456.
PMID: 36064451
PMC: 9446550.
DOI: 10.1186/s13287-022-03133-2.
Zhu Z, Zhan H, Sun A, Huang H, Chen B, Zhang F
Biosci Rep. 2022; 42(6).
PMID: 35543228
PMC: 9202509.
DOI: 10.1042/BSR20220225.
Pan-cancer predictions of transcription factors mediating aberrant DNA methylation.
Detilleux D, Spill Y, Balaramane D, Weber M, Bardet A
Epigenetics Chromatin. 2022; 15(1):10.
PMID: 35331302
PMC: 8944071.
DOI: 10.1186/s13072-022-00443-w.
Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis.
Porras L, Ismail H, Mader S
Cells. 2021; 10(11).
PMID: 34831189
PMC: 8616513.
DOI: 10.3390/cells10112966.
FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer.
Seachrist D, Anstine L, Keri R
Cancers (Basel). 2021; 13(20).
PMID: 34680352
PMC: 8533709.
DOI: 10.3390/cancers13205205.
Overexpression of Predicts Poor Prognosis in Patients with Luminal Breast Cancer.
Lyu L, Wang M, Zheng Y, Tian T, Deng Y, Xu P
Cancer Manag Res. 2020; 12:12457-12471.
PMID: 33299353
PMC: 7721111.
DOI: 10.2147/CMAR.S280009.
Racial Differences in the Association Between Luminal Master Regulator Gene Expression Levels and Breast Cancer Survival.
Byun J, Singhal S, Park S, Yi D, Yan T, Caban A
Clin Cancer Res. 2020; 26(8):1905-1914.
PMID: 31911546
PMC: 8051554.
DOI: 10.1158/1078-0432.CCR-19-0875.
The Quantitative ER Immunohistochemical Analysis in Breast Cancer: Detecting the 3 + 0, 4 + 0, and 5 + 0 Allred Score Cases.
Ilic I, Stojanovic N, Radulovic N, Zivkovic V, Randjelovic P, Petrovic A
Medicina (Kaunas). 2019; 55(8).
PMID: 31405154
PMC: 6722798.
DOI: 10.3390/medicina55080461.
VULCAN integrates ChIP-seq with patient-derived co-expression networks to identify GRHL2 as a key co-regulator of ERa at enhancers in breast cancer.
Holding A, Giorgi F, Donnelly A, Cullen A, Nagarajan S, Selth L
Genome Biol. 2019; 20(1):91.
PMID: 31084623
PMC: 6515683.
DOI: 10.1186/s13059-019-1698-z.
Single Cell Omics of Breast Cancer: An Update on Characterization and Diagnosis.
Dwivedi S, Purohit P, Misra R, Lingeswaran M, Vishnoi J, Pareek P
Indian J Clin Biochem. 2019; 34(1):3-18.
PMID: 30728668
PMC: 6346617.
DOI: 10.1007/s12291-019-0811-0.
The Unfolded Protein Response in Breast Cancer.
McGrath E, Logue S, Mnich K, Deegan S, Jager R, Gorman A
Cancers (Basel). 2018; 10(10).
PMID: 30248920
PMC: 6211039.
DOI: 10.3390/cancers10100344.
TFF1 Promotes EMT-Like Changes through an Auto-Induction Mechanism.
Romano E, Vllahu M, Bizzarro V, Belvedere R, Esposito R, Petrella A
Int J Mol Sci. 2018; 19(7).
PMID: 29997345
PMC: 6073196.
DOI: 10.3390/ijms19072018.
Comprehensive Analysis of the Unfolded Protein Response in Breast Cancer Subtypes.
Jiang D, Turner B, Song J, Li R, Diehn M, Le Q
JCO Precis Oncol. 2018; 2017.
PMID: 29888341
PMC: 5992919.
DOI: 10.1200/PO.16.00073.
A novel / interacting pathway: A study of Oncomine™ breast cancer microarrays.
Chaudhary S, Krishna B, Mishra S
Oncol Lett. 2017; 14(2):1247-1264.
PMID: 28789340
PMC: 5529806.
DOI: 10.3892/ol.2017.6329.
Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study.
Iddawela M, Rueda O, Eremin J, Eremin O, Cowley J, Earl H
BMC Genomics. 2017; 18(1):526.
PMID: 28697743
PMC: 5506605.
DOI: 10.1186/s12864-017-3867-3.
A transcriptional complex composed of ER(α), GATA3, FOXA1 and ELL3 regulates IL-20 expression in breast cancer cells.
Lee J, Park Y, Oh N, Kwack K, Park K
Oncotarget. 2017; 8(26):42752-42760.
PMID: 28514748
PMC: 5522103.
DOI: 10.18632/oncotarget.17459.
Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer.
Patel H, Abduljabbar R, Lai C, Periyasamy M, Harrod A, Gemma C
Clin Cancer Res. 2016; 22(23):5929-5938.
PMID: 27301701
PMC: 5293170.
DOI: 10.1158/1078-0432.CCR-15-1104.